Skip to main content
Clinical Trials/NCT01151657
NCT01151657
Completed
Not Applicable

Probiotics for Irritable Bowel Syndrome

University of Southern Denmark1 site in 1 country150 target enrollmentJanuary 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Irritable Bowel Syndrome
Sponsor
University of Southern Denmark
Enrollment
150
Locations
1
Primary Endpoint
Adequate relief
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The study aims to investigate the effect of probiotics on IBS-patients symptoms compared to placebo, when given for 6 months.

By draw the investigators give IBS patients, in the age of 18-50 years, capsules with either probiotics or placebo. The patients are to take 2x2 capsules / day for 6 months. The patients are followed for 1 year. They are seen after 3, 6 and 12 months, and are followed by means of monthly letters.

The capsules contain 3 different probiotic strains - Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 and Bifidobacterium Bb12. The dose is 2 x 109 - 10 x 109 CFU/capsule.

The hypothesis is, that there is a clinical difference between the group receiving probiotics and the group receiving placebo.

Detailed Description

Background: In management of IBS, no treatments have showed great efficacy. IBS is a non-fatal disease, so safety is a high priority in the choice of treatment. Probiotics is a dietary supplement and have no adverse effects. In some studies it has shown beneficial effect on some of the IBS patients symptoms, but some of the results are questionable. The studies have to be of longer duration, with more patients and the probiotics have to be capsules instead of milk based drinks.

Registry
clinicaltrials.gov
Start Date
January 2009
End Date
June 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Luise Molenberg Begtrup

Doctor

University of Southern Denmark

Eligibility Criteria

Inclusion Criteria

  • Fulfill ROME III criteria
  • age 18-50 years
  • signed informed content

Exclusion Criteria

  • Danger signals (fever, anaemia, weightloss, blod in stools, predisposition for CRC or IBD)
  • abnormal physical examination
  • comorbidity
  • lacking ability to talk and understand danish
  • pregnancy
  • For patients \> 40 years. Changed bowel habits, with duration \> 3 weeks, but \< 1 year

Outcomes

Primary Outcomes

Adequate relief

Time Frame: Every month for 12 months

The patients are asked "In the last seven days, have you had adequate relief of your IBS symptoms?" . They are asked this question every month ( in a monthly letter) for 12 months.

Secondary Outcomes

  • gastrointestinal symptoms(Every month for 12 months)

Study Sites (1)

Loading locations...

Similar Trials